sacituzumab tirumotecan (MK-2870) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
27 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sacituzumab tirumotecan (MK-2870) / Merck (MSD)
SKB264-Ⅲ-10, CTR20232807: To evaluate a randomized, open-label, multicenter phase III clinical trial of SKB264 monotherapy versus investigator choice in patients with unresectable locally advanced, recurrent, or metastatic hormone receptor positive (HR+) human epidermal growth fac

Ongoing
3
376
China
sacituzumab tirumotecan (MK-2870) - Merck (MSD)
Sichuan Kelunbotai Biopharmaceutical Co., Ltd
HR+/HER2- breast cancer
 
 
OptiTROP-Breast01, NCT05347134: SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Active, not recruiting
3
254
RoW
SKB264, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Triple Negative Breast Cancer
10/23
12/24
MK-2870-005, NCT06132958: Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer

Recruiting
3
710
Europe, Canada, Japan, US, RoW
Sacituzumab tirumotecan, SKB264 MK-2870, Doxorubicin, ADRIAMYCIN®, Paclitaxel, TAXOL®
Merck Sharp & Dohme LLC, European Network for Gynaecological Oncological Trial groups(ENGOT), GOG Foundation
Endometrial Cancer
01/28
01/28
MK-2870-007, NCT06170788: Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50%

Recruiting
3
614
Europe, US, RoW
Sacituzumab tirumotecan, SKB264, MK-2870, Pembrolizumab, MK-3475, KEYTRUDA®, SCH 900475
Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC)
01/28
05/30
SKB264-Ⅲ-11, NCT06279364: A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Not yet recruiting
3
524
RoW
SKB264, Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, Carboplatin
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Triple Negative Breast Cancer
07/26
07/26
MK-2870-019, NCT06312137: A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR)

Recruiting
3
780
Europe, US, RoW
Sacituzumab tirumotecan, MK-2870, Pembrolizumab, MK-3475, Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Paclitaxel
Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer
02/34
10/34
MK-2870-010, NCT06312176: A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting
3
1200
Europe, US, RoW
Sacituzumab tirumotecan, MK-2870, Pembrolizumab, MK-3475, KEYTRUDA®, Paclitaxel, TAXOL®, Nab-paclitaxel, ABRAXANE®, Capecitabine, XELODA®, Liposomal doxorubicin, DOXIL®
Merck Sharp & Dohme LLC
Breast Neoplasms
07/27
04/31
MK-2870-015, NCT06356311: A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma

Recruiting
3
450
Europe, US, RoW
Sacituzumab tirumotecan, SKB264. MK-2870, Trifluridine-Tipiracil, Irinotecan, Paclitaxel, Docetaxel
Merck Sharp & Dohme LLC
Gastroesophageal Cancer
01/27
05/28
SKB264-Ⅲ-12, NCT06448312: A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting
3
406
RoW
SKB264, Pembrolizumab
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Non-Small Cell Lung Cancer
11/26
11/26
U1111-1301-2790, NCT06422143: Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Recruiting
3
851
RoW
Pembrolizumab, KEYTRUDA®, MK-3475, SCH 900475, sac-TMT, MK-2870, Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer, NSCLC
01/29
02/31
MK-2870-009, NCT06305754: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

Recruiting
3
520
US, RoW
Sacituzumab tirumotecan, SKB264, MK-2870, Pemetrexed, Carboplatin, Antihistamine, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent)
Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC)
09/28
06/30
U1111-1289-8264, NCT06393374: Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Recruiting
3
1530
US
Pembrolizumab, KEYTRUDA®, MK-3475, SCH 900475, sac-TMT, MK-2870, Sacituzumab tirumotecan, Capecitabine, XELODA
Merck Sharp & Dohme LLC
Triple-Negative Breast Cancer
12/30
12/37
NCT06459180: A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Not yet recruiting
3
686
NA
Sacituzumab Tirumotecan, MK-2870, Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan
Merck Sharp & Dohme LLC, European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Cervical Cancer
10/28
10/28
SKB264-Ⅲ-09, NCT05870319: A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

Recruiting
3
356
RoW
SKB264, Pemetrexed, Carboplatin, Cisplatin
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
05/25
09/26
SKB264-Ⅲ-10, NCT06081959: A Phase III Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

Not yet recruiting
3
376
NA
SKB264, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Metastatic Breast Cancer
03/26
12/27
MK-2870-004, NCT06074588: Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations

Recruiting
3
556
Canada, US, RoW
Sacituzumab tirumotecan, SKB264, MK-2870, Docetaxel, TAXOTERE®, Pemetrexed, ALIMTA®
Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC)
05/27
03/30
OptiTROP-Lung01, NCT05351788: SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Recruiting
2
110
RoW
SKB264, KL-A167, Carboplatin, Cisplatin
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Non-small Cell Lung Cancer
08/24
04/26
NCT06428409: A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A)

Not yet recruiting
2
130
NA
Sacituzumab tirumotecan, MK-2870, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin
Merck Sharp & Dohme LLC
Colorectal Cancer, Pancreatic Ductal Carcinoma, Biliary Tract Cancer
12/28
12/28
SKB264-Ⅱ-08, NCT05631262: SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors

Recruiting
2
366
RoW
SKB264, Docetaxel
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Selected Subjects With Advanced Solid Tumors
10/24
10/25
SKB264-Ⅱ-07, NCT05445908: SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

Recruiting
2
175
RoW
SKB264, KL-A167
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Triple-negative Breast Cancer and HR+/HER2- BC
04/25
07/25
SKB264-II-06, NCT05642780: SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Recruiting
2
184
RoW
SKB264, Pembrolizumab, Keytruda
Klus Pharma Inc.
Solid Tumor
09/25
11/25
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
278
Europe, RoW
SKB264, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate
Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
12/25
08/26
Keymaker-U06, NCT06445972: Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/)

Not yet recruiting
1/2
90
NA
Ramucirumab, Paclitaxel, MK-2870, SKB264, sacituzumab tirumotecan, sac-TMT
Merck Sharp & Dohme LLC
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
12/26
10/28
NCT06469944: Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Not yet recruiting
1/2
130
NA
Pembrolizumab, MK-3475, Keytruda®, Sacituzumab Tirumotecan, MK-2870, SKB264, Capecitabine, XELODA, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, 5-FU, ADRUCIL®
Merck Sharp & Dohme LLC
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
01/27
04/29
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
NCT05319730: A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Recruiting
1/2
200
Europe, Japan, RoW
Paclitaxel, Irinotecan, Pembrolizumab, MK-3475, KEYTRUDA®, MK-4830, anti-immunoglobulin-like transcript 4 (anti-ILT4), Lenvatinib, MK-7902, LENVIMA®, Sacituzumab tirumotecan, SKB264, MK-2870, Antihistamine, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent)
Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma
11/26
09/28
NCT06049212: Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

Recruiting
1
36
Japan
Sacituzumab tirumotecan, SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin
Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1(PDL1, PD-L1), Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
06/25
06/25

Download Options